Biomarin Pharmaceutical (BMRN) Total Current Liabilities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Total Current Liabilities across 18 years of filings, most recently posting $793.2 million for Q1 2026.

• Quarterly Total Current Liabilities rose 26.26% year-over-year to $793.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $793.2 million (up 26.26% YoY) and the FY2025 annual result came in at $759.0 million, up 25.05% from the prior year.
• Total Current Liabilities climbed to $793.2 million in Q1 2026, from $759.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $1.2 billion in Q4 2023 and troughed at $464.7 million in Q2 2022.
• A 5-year average of $749.5 million and a median of $684.2 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 123.26% — and 2024, when it slumped 48.43%.
• Tracing BMRN's Total Current Liabilities over 5 years: stood at $588.9 million in 2022, then jumped by 99.87% to $1.2 billion in 2023, then slumped by 48.43% to $607.0 million in 2024, then climbed by 25.05% to $759.0 million in 2025, then gained by 4.5% to $793.2 million in 2026.
• Business Quant data shows BMRN's Total Current Liabilities at $793.2 million in Q1 2026, $759.0 million in Q4 2025, and $798.4 million in Q3 2025.